Clinical characteristics of expression microarray studies
| Total n=1016 | AMS_cDNA (n=34) | AU_affy (n=68) | HK_cDNA (n=90) | Korea_SY (n=96) | SamsungMC (n=432) | SGset1 (n=152) | SGset2 (n=55) | YGC (n=65) | LEEDS (n=24) | p Value* (t test) |
|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | ||||||||||
| Range | 50.0–90.5 | 32.0–85.0 | 35.0–88.0 | 30.0–90.0 | 23.0–74.0 | 23.4–92.4 (1 missing) | 43.0–85.0 | 32.0–83.0 | 53.0–83.7 | – |
| Mean±SD | 72.2±8.8 | 65.0±12.4 | 68.5±11.9 | 63.2±10.6 | 51.9±10.7 | 65.6±12.9 (1 missing) | 68.7±9.1 | 61.0±11.5 | 72.5±8.5 | 0.10 |
| Gender (%) | ||||||||||
| Female | 10 (29.4) | 20 (29.4) | 39 (43.3) | 26 (27.1) | 152 (35.2) | 59 (38.8) | 20 (36.4) | 19 (29.2) | 11 (45.8) | 0.98 |
| Male | 24 (70.6) | 48 (70.6) | 51 (56.7) | 70 (72.9) | 280 (64.8) | 92 (60.5) | 35 (63.6) | 46 (70.8) | 13 (54.2) | 0.97 |
| Missing | – | – | – | – | – | 1 (0.66) | – | – | – | – |
| Stage† (%) | ||||||||||
| I | 6 (17.6) | 11 (16.2) | 13 (14.4) | 8 (8.33) | 55 (12.7) | 27 (17.8) | 9 (16.4) | 12 (18.5) | 5 (20.8) | 0.14 |
| II | 7 (20.6) | 15 (22.1) | 19 (21.1) | 22 (22.9) | 160 (37.0) | 22 (14.5) | 12 (21.8) | 2 (3.08) | 4 (16.7) | 0.96 |
| III | 12 (35.3) | 35 (51.5) | 43 (47.8) | 37 (38.5) | 144 (33.3) | 54 (35.5) | 18 (32.7) | 35 (53.8) | 12 (50.0) | 0.44 |
| IV | 9 (26.5) | 7 (10.3) | 15 (16.7) | 29 (30.2) | 72 (16.7) | 48 (31.6) | 15 (27.3) | 16 (24.6) | 3 (12.5) | 0.25 |
| Missing | – | – | – | – | 1 (0.23) | 1 (0.66) | 1 (1.82) | – | – | – |
| Lauren's histopathology (%) | ||||||||||
| Intestinal | 16 (47.1) | 33 (48.5) | 68 (75.6) | 32 (33.3) | 139 (32.2) | 79 (52.0) | 38 (69.1) | 20 (30.8) | 17 (70.8) | 0.57 |
| Diffuse | 12 (35.3) | 29 (42.6) | 13 (14.4) | 21 (21.9) | 280 (64.8) | 56 (36.8) | 11 (20.0) | 31 (47.7) | 5 (20.8) | 0.90 |
| Mixed/unclassifiable | 6 (17.6) | 6 (8.82) | 9 (10.0) | 43 (44.8) | 13 (3.01) | 16 (10.5) | 5 (9.09) | 12 (18.5) | 2 (8.33) | 0.54 |
| Missing | – | – | – | – | – | 1 (0.66) | 1 (1.82) | 2 (3.08) | – | – |
| Helicobacter Pylori status (%) | ||||||||||
| Positive | – | 49 (72.1) | 48 (53.3) | – | – | 48 (31.6) | 19 (34.5) | – | – | N.A. |
| Negative | – | 17 (25.0) | 42 (46.7) | – | – | 25 (16.4) | 6 (10.9) | – | – | N.A. |
| Missing/ unknown | – | 2 (2.94) | – | – | – | 79 (52.0) | 30 (54.5) | – | – | – |
| Tumour location (%) | ||||||||||
| Upper third | 11 (32.4) | 19 (27.9) | 28 (31.1) | – | 54 (12.5) | 15 (9.87) | 9 (16.4) | 4 (6.15) | 6 (25.0) | 0.04 |
| Middle third | 15 (44.1) | 36 (52.9) | – | – | 115 (26.6) | 67 (44.1) | 11 (20.0) | 31 (47.7) | 9 (37.5) | 0.26 |
| Lower third | 10 (29.4) | 12 (17.6) | 41 (45.6) | – | 226 (52.3) | 37 (24.3) | 15 (27.3) | 27 (41.5) | 8 (33.3) | 0.16 |
| Others‡ | – | 1 (1.47) | – | – | 37 (8.56) | 22 (14.5) | – | 1 (1.54) | – | N.A. |
| Missing | 8 (23.5) | – | 21 (23.3) | – | – | 11 (7.24) | 20 (36.4) | 2 (3.08) | 1 (4.17) | – |
| Tumour differentiation (%) | ||||||||||
| Well | 1 (2.94) | 2 (2.94) | – | 12 (12.5) | 10 (2.31) | 5 (3.29) | 1 (1.82) | 20 (30.8) | 2 (8.33) | 0.40 |
| Moderate | 10 (29.4) | 22 (32.4) | – | 33 (34.4) | 108 (25.0) | 54 (35.5) | 23 (41.8) | 15 (23.1) | 12 (50.0) | 0.52 |
| Poor/undifferentiated | 22 (64.7) | 44 (64.7) | – | 43 (44.8) | 186 (43.1) | 90 (59.2) | 29 (52.7) | 6 (9.23) | 10 (41.7) | 0.24 |
| Others§ | – | – | – | 8 (8.33) | 127 (29.4) | – | – | 20 (30.8) | – | N.A. |
| Missing | 1 (2.94) | – | – | 1 (0.23) | 3 (1.97) | 2 (3.64) | 4 (6.15) | – | – | |
*p-value from hypothesis testing between Asian and non-Asian cohorts.
†American Joint Committee on Cancer (AJCC) staging 6th edition.
‡Include whole stomach, anastomosis, multisite, etc.
§Other mixed signet-ring, mucinous, tubular, hepatoid etc. non-conventional classifications as provided by the original study investigators. These have not been reviewed, thus may not be 100% comparable between studies due to differing local practice.